##SAMPLE=<ID=DX183978_01,Gender=male,ExternalSampleName=DNA-183978 A1,IsTumor=yes,IsFFPE=yes,DiseaseGroup=n/a,DiseaseStatus=n/a>
##SAMPLE=<ID=DX183927_01,Gender=male,ExternalSampleName=DNA-183927 A1,IsTumor=no,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=n/a>
##ANALYSISTYPE=SOMATIC_PAIR
##PIPELINE=megSAP 0.1-802-g8d2abb4
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample DX183978_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample DX183978_01).
##DESCRIPTION=normal_af=Mutant allele frequency in normal (Sample DX183927_01).
##DESCRIPTION=normal_dp=Normal depth (Sample DX183927_01).
##DESCRIPTION=filter=Filter criteria from vcf file.
##DESCRIPTION=snp_q=Quality parameters - SNP quality (QUAL).
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon number, HGVS.c, HGVS.p).
##DESCRIPTION=interpro=Interpro domains.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in all populations of 1000g project.
##DESCRIPTION=ExAC=Allele frequency in all populations of ExAC project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD database.
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=MetaLR=MetaLR effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=Sift=Sift effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen2=Polyphen2 (HVAR) effect prediction: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=FATHMM=FATHMM effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 15-20.
##DESCRIPTION=ihdb_hom=Homozygous variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_het=Heterozyous variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_wt=Wildtype variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_allsys_hom=Homozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=ihdb_allsys_het=Heterozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validated=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Comments from the NGSD. Comments of other samples are listed in brackets!
##DESCRIPTION=gene_info=General gene information from the NGSD.
##DESCRIPTION=som_ihdb_c=Somatic variant count within NGSD.
##DESCRIPTION=som_ihdb_p=Projects with somatic variant in NGSD.
##FILTER=all-unknown=Allele unknown (filter_vcf).
##FILTER=depth-nor=Sequencing depth normal is too low < 20 (filter_vcf).
##FILTER=depth-tum=Sequencing depth tumor is too low < 20 (filter_vcf).
##FILTER=freq-nor=Allele frequencies in tumor < 0.05 or allele frequencies in normal > 0.01 (filter_vcf).
##FILTER=freq-tum=Allele frequencies in tumor < 0.05 or allele frequencies in normal > 0.01 (filter_vcf).
##FILTER=lt-3-reads=Less than 3 supporting tumor reads (filter_vcf).
##FILTER=off-target=Variant marked as 'off-target'.
##FILTER=special-chromosome=Special chromosome.
##CGI_CANCER_TYPE=CM
##DESCRIPTION=CGI_id=Identifier for CGI statements
##DESCRIPTION=CGI_driver_statement=CancerGenomeInterpreter.org oncogenic classification
##DESCRIPTION=CGI_gene_role=CancerGenomeInterpreter.org gene role. LoF: Loss of Function, Act: Activating
##DESCRIPTION=CGI_transcript=CancerGenomeInterpreter.org CGI Ensembl transcript ID
##DESCRIPTION=CGI_gene=Gene symbol returned by CancerGenomeInterpreter.org
##DESCRIPTION=CGI_consequence=Consequence of the mutation assessed by CancerGenomeInterpreter.org
#chr	start	end	ref	obs	tumor_af	tumor_dp	normal_af	normal_dp	filter	snp_q	gene	variant_type	coding_and_splicing	interpro	Pathway_KEGG_full	Function_description	Pathway_BioCarta_full	RepeatMasker	dbSNP	1000g	ExAC	gnomAD	COSMIC	OMIM	ClinVar	HGMD	phyloP	MetaLR	Sift	PolyPhen2	FATHMM	CADD	ihdb_hom	ihdb_het	ihdb_wt	ihdb_allsys_hom	ihdb_allsys_het	classification	classification_comment	validated	comment	gene_info	som_ihdb_c	som_ihdb_p	CGI_driver_statement	CGI_gene_role	CGI_transcript	CGI_gene	CGI_consequence
chr1	11854013	11854013	G	A	0.2817	252	0.0000	184		245	MTHFR,C1orf167	missense_variant,downstream_gene_variant	MTHFR:ENST00000376583:missense_variant:MODERATE:exon9/12:c.1604C>T:p.Ser535Phe,MTHFR:ENST00000376592:missense_variant:MODERATE:exon8/11:c.1481C>T:p.Ser494Phe,MTHFR:ENST00000376590:missense_variant:MODERATE:exon9/12:c.1481C>T:p.Ser494Phe,MTHFR:ENST00000376585:missense_variant:MODERATE:exon10/13:c.1604C>T:p.Ser535Phe,C1orf167:ENST00000433342:downstream_gene_variant:MODIFIER::c.*4510G>A:,C1orf167:ENST00000312793:downstream_gene_variant:MODIFIER::c.*4510G>A:,C1orf167:ENST00000444493:downstream_gene_variant:MODIFIER::c.*4510G>A:,C1orf167:ENST00000449278:downstream_gene_variant:MODIFIER::c.*4497G>A:,C1orf167:ENST00000482358:downstream_gene_variant:MODIFIER::n.*4371G>A:		One carbon pool by folate;Methane metabolism	Catalyzes the conversion of 5,10- methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co- substrate for homocysteine remethylation to methionine				0.0000	0.0000	0.0000		607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];			9.338000	T	D,D,D,D	P,P	T,T,T,T	26.20				0	0					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.15)	0		predicted passenger		ENST00000376592	MTHFR	Missense
chr1	23239911	23239911	C	T	0.3074	245	0.0000	237	off-target	304	EPHB2,RP1-74M1.3	3_prime_UTR_variant,upstream_gene_variant,intron_variant	EPHB2:ENST00000374627:3_prime_UTR_variant:MODIFIER:exon15/15:c.*815C>T:,RP1-74M1.3:ENST00000610135:upstream_gene_variant:MODIFIER::n.-3264C>T:,EPHB2:ENST00000400191:intron_variant:MODIFIER:exon15/16:c.2853-44C>T:,EPHB2:ENST00000374630:intron_variant:MODIFIER:exon15/15:c.2853-44C>T:,EPHB2:ENST00000374632:intron_variant:MODIFIER:exon15/15:c.2856-44C>T:		Axon guidance	Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Functions in axon guidance during development. Involved in the guidance of commissural axons, that form a major interhemispheric connection between the 2 temporal lobes of the cerebral cortex. Also involved in guidance of contralateral inner ear efferent growth cones at the midline and of retinal ganglion cell axons to the optic disk. Beside axon guidance, also regulates dendritic spines development and maturation and stimulates the formation of excitatory synapses. Upon activation by EFNB1, abolishes the ARHGEF15-mediated negative regulation on excitatory synapse formation. Controls other aspects of development including angiogenesis, palate development and in inner ear development through regulation of endolymph production. Forward and reverse signaling through the EFNB2/EPHB2 complex regulate movement and adhesion of cells that tubularize the urethra and septate the cloaca. May function as a tumor suppressor				0.0000	0.0000	0.0000		600997 [EPHB2 (confirmed) Prostate cancer/brain cancer susceptibility,somatic,603688];												0	0					EPHB2 (inh=n/a pLI=1.00), RP1-74M1.3 (inh=n/a pLI=n/a)	0						
chr1	23240293	23240293	G	-	0.2958	278	0.0028	382		342	EPHB2,RP1-74M1.3	frameshift_variant,3_prime_UTR_variant,upstream_gene_variant,downstream_gene_variant	EPHB2:ENST00000400191:frameshift_variant:HIGH:exon17/17:c.3100delG:p.Glu1034fs,EPHB2:ENST00000374632:3_prime_UTR_variant:MODIFIER:exon16/16:c.*232delG:,RP1-74M1.3:ENST00000610135:upstream_gene_variant:MODIFIER::n.-2882delG:,EPHB2:ENST00000374630:downstream_gene_variant:MODIFIER::c.*230delG:,EPHB2:ENST00000374627:downstream_gene_variant:MODIFIER::c.*1197delG:		Axon guidance	Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Functions in axon guidance during development. Involved in the guidance of commissural axons, that form a major interhemispheric connection between the 2 temporal lobes of the cerebral cortex. Also involved in guidance of contralateral inner ear efferent growth cones at the midline and of retinal ganglion cell axons to the optic disk. Beside axon guidance, also regulates dendritic spines development and maturation and stimulates the formation of excitatory synapses. Upon activation by EFNB1, abolishes the ARHGEF15-mediated negative regulation on excitatory synapse formation. Controls other aspects of development including angiogenesis, palate development and in inner ear development through regulation of endolymph production. Forward and reverse signaling through the EFNB2/EPHB2 complex regulate movement and adhesion of cells that tubularize the urethra and septate the cloaca. May function as a tumor suppressor				0.0000	0.0000	0.0000		600997 [EPHB2 (confirmed) Prostate cancer/brain cancer susceptibility,somatic,603688];												0	0					EPHB2 (inh=n/a pLI=1.00), RP1-74M1.3 (inh=n/a pLI=n/a)	0		not protein-affecting	Act	ENST00000374632	EPHB2	3-UTRDeletion
chr1	23240295	23240295	G	A	0.2930	268	0.0000	383		276	EPHB2,RP1-74M1.3	missense_variant,3_prime_UTR_variant,upstream_gene_variant,downstream_gene_variant	EPHB2:ENST00000400191:missense_variant:MODERATE:exon17/17:c.3100G>A:p.Glu1034Lys,EPHB2:ENST00000374632:3_prime_UTR_variant:MODIFIER:exon16/16:c.*232G>A:,RP1-74M1.3:ENST00000610135:upstream_gene_variant:MODIFIER::n.-2880G>A:,EPHB2:ENST00000374630:downstream_gene_variant:MODIFIER::c.*232G>A:,EPHB2:ENST00000374627:downstream_gene_variant:MODIFIER::c.*1199G>A:		Axon guidance	Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Functions in axon guidance during development. Involved in the guidance of commissural axons, that form a major interhemispheric connection between the 2 temporal lobes of the cerebral cortex. Also involved in guidance of contralateral inner ear efferent growth cones at the midline and of retinal ganglion cell axons to the optic disk. Beside axon guidance, also regulates dendritic spines development and maturation and stimulates the formation of excitatory synapses. Upon activation by EFNB1, abolishes the ARHGEF15-mediated negative regulation on excitatory synapse formation. Controls other aspects of development including angiogenesis, palate development and in inner ear development through regulation of endolymph production. Forward and reverse signaling through the EFNB2/EPHB2 complex regulate movement and adhesion of cells that tubularize the urethra and septate the cloaca. May function as a tumor suppressor				0.0000	0.0000	0.0000		600997 [EPHB2 (confirmed) Prostate cancer/brain cancer susceptibility,somatic,603688];			2.785000	T	D	B	T	14.28				0	0					EPHB2 (inh=n/a pLI=1.00), RP1-74M1.3 (inh=n/a pLI=n/a)	0		not protein-affecting	Act	ENST00000374632	EPHB2	3-UTRSNV
chr1	27100281	27100281	T	A	0.3071	1700	0.0008	1189		1420	ARID1A	upstream_gene_variant,intron_variant	ARID1A:ENST00000532781:upstream_gene_variant:MODIFIER::c.-1082T>A:,ARID1A:ENST00000324856:intron_variant:MODIFIER:exon16/19:c.4005-12T>A:,ARID1A:ENST00000457599:intron_variant:MODIFIER:exon16/19:c.4005-12T>A:,ARID1A:ENST00000374152:intron_variant:MODIFIER:exon15/18:c.2856-12T>A:,ARID1A:ENST00000430799:intron_variant:MODIFIER:exon5/8:c.693-12T>A:,ARID1A:ENST00000540690:intron_variant:MODIFIER:exon3/5:c.-120-12T>A:,ARID1A:ENST00000466382:intron_variant:MODIFIER:exon3/5:c.312-12T>A:			Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Binds DNA non-specifically. Also involved in vitamin D- coupled transcription regulation via its association with the WINAC complex, a chromatin-remodeling complex recruited by vitamin D receptor (VDR), which is required for the ligand-bound VDR- mediated transrepression of the CYP27B1 gene. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a post-mitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to post-mitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity)				0.0000	0.0000	0.0000		603024 [ARID1A (provisional) Coffin-Siris syndrome 2,614607];												0	0					ARID1A (inh=AD pLI=1.00)	0		not protein-affecting	LoF	ENST00000324856	ARID1A	IntronicSNV
chr1	31960385	31960385	C	T	0.2389	113	0.0000	62	off-target	112	RP11-439L8.2,SERINC2-RP11-439L8.2	downstream_gene_variant,intergenic_region	RP11-439L8.2:ENST00000401075:downstream_gene_variant:MODIFIER::n.*51G>A:,SERINC2-RP11-439L8.2:ENSG00000168528-ENSG00000215899:intergenic_region:MODIFIER::n.31960385C>T:							0.0000	0.0000	0.0000														0	0					RP11-439L8.2 (inh=n/a pLI=n/a), SERINC2-RP11-439L8.2 (inh=n/a pLI=n/a)	0						
chr1	35817236	35817236	C	T	0.2533	75	0.0000	62	off-target	110	RPL5P4,ZMYM4	downstream_gene_variant,intron_variant	RPL5P4:ENST00000434805:downstream_gene_variant:MODIFIER::n.*28C>T:,ZMYM4:ENST00000314607:intron_variant:MODIFIER:exon2/29:c.86-7290C>T:,ZMYM4:ENST00000373297:intron_variant:MODIFIER:exon2/27:c.86-7290C>T:,ZMYM4:ENST00000441447:intron_variant:MODIFIER:exon3/3:c.-11-7290C>T:			Plays a role in the regulation of cell morphology and cytoskeletal organization				0.0000	0.0000	0.0000														0	0					RPL5P4 (inh=n/a pLI=n/a), ZMYM4 (inh=n/a pLI=1.00)	0						
chr1	43803618	43803618	G	A	0.3520	197	0.0000	282		354	MPL	intron_variant	MPL:ENST00000372470:intron_variant:MODIFIER:exon1/11:c.79+20G>A:,MPL:ENST00000413998:intron_variant:MODIFIER:exon1/9:c.79+20G>A:		Cytokine-cytokine receptor interaction;Jak-STAT signaling pathway	Receptor for thrombopoietin. May represent a regulatory molecule specific for TPO-R-dependent immune responses	TPO Signaling Pathway		rs745880889	0.0000	0.00001	0.00001		159530 [MPL (confirmed) Thrombocytopenia,congenital amegakaryocytic,604498|Thrombocythemia 2,601977|Myelofibrosis with myeloid metaplasia,somatic,254450];												0	0					MPL (inh=AR+AD pLI=0.00)	0		not protein-affecting	Act	ENST00000372470	MPL	IntronicSNV
chr1	55509524	55509524	G	A	0.3474	287	0.0000	351		439	PCSK9	stop_gained,intron_variant	PCSK9:ENST00000302118:stop_gained:HIGH:exon2/12:c.216G>A:p.Trp72*,PCSK9:ENST00000452118:stop_gained:HIGH:exon2/6:c.216G>A:p.Trp72*,PCSK9:ENST00000543384:intron_variant:MODIFIER:exon1/9:c.-78+3448G>A:			Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways				0.0000	0.0000	0.0000		607786 [PCSK9 (confirmed) Hypercholesterolemia,familial,3,603776|Low density lipoprotein cholesterol level QTL 1,603776];			7.428000					36.00				0	0					PCSK9 (inh=AD pLI=0.00)	0		predicted passenger		ENST00000302118	PCSK9	Nonsense
chr1	78433361	78433361	A	C	0.3243	148	0.0000	93		170	FUBP1	sequence_feature,intron_variant	FUBP1:ENST00000294623:sequence_feature:MODERATE:exon3/20:c.251-11T>G:,FUBP1:ENST00000436586:intron_variant:MODIFIER:exon4/20:c.314-11T>G:,FUBP1:ENST00000294623:intron_variant:MODIFIER:exon3/20:c.251-11T>G:,FUBP1:ENST00000370768:intron_variant:MODIFIER:exon3/19:c.251-11T>G:,FUBP1:ENST00000370767:intron_variant:MODIFIER:exon3/19:c.251-11T>G:,FUBP1:ENST00000421641:intron_variant:MODIFIER:exon4/8:c.314-11T>G:		Glycolysis / Gluconeogenesis;Pentose phosphate pathway;Fructose and mannose metabolism;Carbon fixation;Insulin signaling pathway	Regulates MYC expression by binding to a single-stranded far-upstream element (FUSE) upstream of the MYC promoter. May act both as activator and repressor of transcription				0.0000	0.0000	0.0000														0	0					FUBP1 (inh=n/a pLI=1.00)	0		not protein-affecting	LoF	ENST00000370768	FUBP1	IntronicSNV
chr1	96913533	96913533	C	T	0.3333	523	0.0000	437	off-target	553	EEF1A1P11	non_coding_transcript_exon_variant	EEF1A1P11:ENST00000415278:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1048C>T:							0.0000	0.0000	0.0000														0	0					EEF1A1P11 (inh=n/a pLI=n/a)	0						
chr1	97771541	97771541	C	T	0.2609	23	0.0000	51	off-target	90	DPYD,DPYD-AS1	intron_variant	DPYD:ENST00000370192:intron_variant:MODIFIER:exon17/22:c.2179+192G>A:,DPYD-AS1:ENST00000422980:intron_variant:MODIFIER:exon2/4:n.129-204C>T:		Pyrimidine metabolism;beta-Alanine metabolism;Pantothenate and CoA biosynthesis;Drug metabolism - other enzymes	Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil				0.0000	0.0000	0.0000		612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];												0	0					DPYD (inh=AR pLI=0.00), DPYD-AS1 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,					
chr1	98165741	98165741	C	T	0.2896	627	0.0000	293		397	DPYD	splice_region_variant&intron_variant,intron_variant	DPYD:ENST00000423006:splice_region_variant&intron_variant:LOW:exon5/6:c.*14+5G>A:,DPYD:ENST00000370192:intron_variant:MODIFIER:exon5/22:c.484-638G>A:,DPYD:ENST00000474241:intron_variant:MODIFIER:exon2/3:n.248-638G>A:		Pyrimidine metabolism;beta-Alanine metabolism;Pantothenate and CoA biosynthesis;Drug metabolism - other enzymes	Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil				0.0000	0.0000	0.0000		612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];												0	0					DPYD (inh=AR pLI=0.00)	0		not protein-affecting	ambiguous	ENST00000370192	DPYD	IntronicSNV
chr1	115256529	115256529	T	C	0.3283	1807	0.0023	868		1199	NRAS,CSDE1	missense_variant,downstream_gene_variant	NRAS:ENST00000369535:missense_variant:MODERATE:exon3/7:c.182A>G:p.Gln61Arg,CSDE1:ENST00000438362:downstream_gene_variant:MODIFIER::c.*4261A>G:,CSDE1:ENST00000339438:downstream_gene_variant:MODIFIER::c.*4261A>G:,CSDE1:ENST00000358528:downstream_gene_variant:MODIFIER::c.*4261A>G:,CSDE1:ENST00000261443:downstream_gene_variant:MODIFIER::c.*4261A>G:,CSDE1:ENST00000530886:downstream_gene_variant:MODIFIER::c.*4261A>G:,CSDE1:ENST00000369530:downstream_gene_variant:MODIFIER::c.*4261A>G:,CSDE1:ENST00000483407:downstream_gene_variant:MODIFIER::n.*3894A>G:,CSDE1:ENST00000534699:downstream_gene_variant:MODIFIER::c.*4261A>G:	Small_GTP-binding_protein_domain__1_	MAPK signaling pathway;ErbB signaling pathway;Axon guidance;VEGF signaling pathway;Tight junction;Gap junction;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Long-term potentiation;Long-term depression;Regulation of actin cytoskeleton;Insulin signaling pathway;GnRH signaling pathway;Melanogenesis;Renal cell carcinoma;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.,RNA-binding protein. Required for internal initiation of translation of human rhinovirus RNA. May be involved in translationally coupled mRNA turnover. Implicated with other RNA- binding proteins in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA mediated by the major coding- region determinant of instability (mCRD) domain			rs11554290	0.0000	0.0000	0.0000	COSM584	164790 [NRAS (confirmed) RAS-associated autoimmune lymphoproliferative syndrome type IV,somatic,614470|Noonan syndrome 6,613224|Epidermal nevus,somatic,162900|Thyroid carcinoma,follicular,somatic,188470|Colorectal cancer,somatic,114500|Melanocytic nevus syndrome,congenital,somatic,137550|Neurocutaneous melanosis,somatic,249400|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200];	13900 [pathogenic DISEASE=acute_myeloid_leukemia,chronic_lymphocytic_leukemia,renal_cell_carcinoma,_papillary,_1,congenital_giant_melanocytic_nevus,follicular_thyroid_carcinoma,transitional_cell_carcinoma_of_the_bladder,adrenocortical_carcinoma,multiple_myeloma,epidermal_nevus,cutaneous_melanoma,lung_adenocarcinoma,non-small_cell_lung_cancer,neoplasm_of_brain,glioblastoma,malignant_melanoma_of_skin,nasopharyngeal_neoplasms,colorectal_neoplasms,malignant_neoplasm_of_body_of_uterus,epidermal_nevus_syndrome,adenocarcinoma_of_stomach,ovarian_serous_cystadenocarcinoma,neurocutaneous_melanosis,hepatocellular_carcinoma,not_provided]; 		7.761000	D	D	B	D	23.10				0	1					NRAS (inh=AD pLI=0.90), CSDE1 (inh=n/a pLI=1.00)	14	I17R008,Roecken_CheckpointInhibitor,SomaticAndTreatment,eMed-HCC,	known in: THF;CM;COREAD;NSCLC;THCA;AML	Act	ENST00000369535	NRAS	Missense
chr1	120465067	120465067	C	T	0.2998	450	0.0000	333		391	NOTCH2	missense_variant&splice_region_variant,downstream_gene_variant	NOTCH2:ENST00000256646:missense_variant&splice_region_variant:MODERATE:exon28/34:c.5005G>A:p.Glu1669Lys,NOTCH2:ENST00000493703:downstream_gene_variant:MODIFIER::n.*51G>A:	Notch__NODP_domain__1_	Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity). Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and positively regulates RANKL-induced osteoclast differentiation				0.0000	0.0000	0.0000		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205|Hajdu-Cheney syndrome,102500];			5.682000	T	T	B	T	22.60				0	0					NOTCH2 (inh=AD pLI=1.00)	0		predicted passenger	ambiguous	ENST00000256646	NOTCH2	Missense
chr1	147282549	147282549	G	A	0.2203	236	0.0000	248	off-target	199	RP11-433J22.3-RP11-314N2.2	intergenic_region	RP11-433J22.3-RP11-314N2.2:ENSG00000234190-ENSG00000223728:intergenic_region:MODIFIER::n.147282549G>A:							0.0000	0.0000	0.0000														0	0					RP11-433J22.3-RP11-314N2.2 (inh=n/a pLI=n/a)	0						
chr1	149858196	149858196	G	C	0.4375	32	0.0000	20	off-target	43	HIST2H2BE,HIST2H2AC,BOLA1,HIST2H2AB	5_prime_UTR_variant,upstream_gene_variant,downstream_gene_variant	HIST2H2BE:ENST00000369155:5_prime_UTR_variant:MODIFIER:exon1/1:c.-6C>G:,HIST2H2AC:ENST00000331380:upstream_gene_variant:MODIFIER::c.-329G>C:,BOLA1:ENST00000369153:upstream_gene_variant:MODIFIER::c.-13417G>C:,HIST2H2AB:ENST00000331128:downstream_gene_variant:MODIFIER::c.*878C>G:			Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling			rs587639035	0.0000	0.00002	0.00001														0	0					HIST2H2BE (inh=n/a pLI=0.49), HIST2H2AC (inh=n/a pLI=0.20), BOLA1 (inh=n/a pLI=0.62), HIST2H2AB (inh=n/a pLI=0.21)	0						
chr1	157514217	157514217	G	A	0.3393	56	0.0000	33	off-target	75	FCRL5	missense_variant,downstream_gene_variant,non_coding_transcript_exon_variant	FCRL5:ENST00000356953:missense_variant:MODERATE:exon5/17:c.679C>T:p.Arg227Cys,FCRL5:ENST00000361835:missense_variant:MODERATE:exon5/17:c.679C>T:p.Arg227Cys,FCRL5:ENST00000368190:missense_variant:MODERATE:exon5/10:c.679C>T:p.Arg227Cys,FCRL5:ENST00000368191:missense_variant:MODERATE:exon4/9:c.424C>T:p.Arg142Cys,FCRL5:ENST00000368189:missense_variant:MODERATE:exon5/8:c.679C>T:p.Arg227Cys,FCRL5:ENST00000368188:downstream_gene_variant:MODIFIER::c.*1786C>T:,FCRL5:ENST00000481082:non_coding_transcript_exon_variant:MODIFIER:exon6/7:n.877C>T:	Immunoglobulin-like__1_,Immunoglobulin-like_fold__1_		May be involved in B-cell development and differentiation in peripheral lymphoid organs and may be useful markers of B-cell stages. May have an immunoregulatory role in marginal zone B-cells			rs746634732	0.0000	0.00004	0.00003	COSM1472794				-0.891000	T	T,T,T,T,T	B,B,B,B,B	T,T,T,T,T	3.45				0	0					FCRL5 (inh=n/a pLI=0.00)	0						
chr1	157599750	157599750	C	T	0.1667	30	0.0000	62	off-target	82	RP4-801G22.2	non_coding_transcript_exon_variant	RP4-801G22.2:ENST00000445687:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.484G>A:							0.0000	0.0000	0.0000														0	0					RP4-801G22.2 (inh=n/a pLI=n/a)	0						
chr1	158325588	158325588	C	T	0.2000	45	0.0000	48	off-target	86	CD1E	upstream_gene_variant,downstream_gene_variant,intron_variant	CD1E:ENST00000368162:upstream_gene_variant:MODIFIER::c.-97C>T:,CD1E:ENST00000464822:downstream_gene_variant:MODIFIER::n.*460C>T:,CD1E:ENST00000368167:intron_variant:MODIFIER:exon3/5:c.626-29C>T:,CD1E:ENST00000434258:intron_variant:MODIFIER:exon3/3:c.620-29C>T:,CD1E:ENST00000444681:intron_variant:MODIFIER:exon2/4:c.329-29C>T:,CD1E:ENST00000452291:intron_variant:MODIFIER:exon1/3:c.59-29C>T:,CD1E:ENST00000368165:intron_variant:MODIFIER:exon2/4:c.356-29C>T:,CD1E:ENST00000368166:intron_variant:MODIFIER:exon1/3:c.59-29C>T:,CD1E:ENST00000368163:intron_variant:MODIFIER:exon3/5:c.626-29C>T:,CD1E:ENST00000368164:intron_variant:MODIFIER:exon1/3:c.59-29C>T:,CD1E:ENST00000368154:intron_variant:MODIFIER:exon1/3:c.59-29C>T:,CD1E:ENST00000368155:intron_variant:MODIFIER:exon2/4:c.356-29C>T:,CD1E:ENST00000368156:intron_variant:MODIFIER:exon2/4:c.356-29C>T:,CD1E:ENST00000368157:intron_variant:MODIFIER:exon1/3:c.59-29C>T:,CD1E:ENST00000368160:intron_variant:MODIFIER:exon3/5:c.626-29C>T:,CD1E:ENST00000368161:intron_variant:MODIFIER:exon3/5:c.626-29C>T:		Hematopoietic cell lineage	T-cell surface glycoprotein CD1e, soluble binds diacetylated lipids, including phosphatidyl inositides and diacylated sulfoglycolipids, and is required for the presentation of glycolipid antigens on the cell surface. The membrane- associated form is not active				0.0000	0.0000	0.0000														0	0					CD1E (inh=n/a pLI=0.00)	1	I18R015_Higuita,					
chr1	158584974	158584974	C	T	0.3343	348	0.0000	248	off-target	318	SPTA1	upstream_gene_variant,downstream_gene_variant,intron_variant,non_coding_transcript_exon_variant	SPTA1:ENST00000485680:upstream_gene_variant:MODIFIER::n.-3159G>A:,SPTA1:ENST00000481212:upstream_gene_variant:MODIFIER::n.-649G>A:,SPTA1:ENST00000484520:downstream_gene_variant:MODIFIER::n.*4002G>A:,SPTA1:ENST00000368147:intron_variant:MODIFIER:exon48/51:c.6788+32G>A:,SPTA1:ENST00000498708:intron_variant:MODIFIER:exon2/4:n.220+32G>A:,SPTA1:ENST00000492934:non_coding_transcript_exon_variant:MODIFIER:exon3/3:n.335G>A:			Spectrin is the major constituent of the cytoskeletal network underlying the erythrocyte plasma membrane. It associates with band 4.1 and actin to form the cytoskeletal superstructure of the erythrocyte plasma membrane				0.0000	0.0000	0.00000		182860 [SPTA1 (confirmed) Elliptocytosis-2,130600|Pyropoikilocytosis,266140|Spherocytosis,type 3,270970];												0	0					SPTA1 (inh=AR+AD pLI=0.00)	0						
chr1	158588034	158588034	C	T	0.3333	9	0.0000	15	depth-tum;depth-nor;off-target	32	SPTA1	upstream_gene_variant,downstream_gene_variant,intron_variant	SPTA1:ENST00000481212:upstream_gene_variant:MODIFIER::n.-3709G>A:,SPTA1:ENST00000498708:upstream_gene_variant:MODIFIER::n.-676G>A:,SPTA1:ENST00000492934:upstream_gene_variant:MODIFIER::n.-143G>A:,SPTA1:ENST00000484520:downstream_gene_variant:MODIFIER::n.*942G>A:,SPTA1:ENST00000461624:downstream_gene_variant:MODIFIER::n.*4475G>A:,SPTA1:ENST00000368147:intron_variant:MODIFIER:exon45/51:c.6531-188G>A:			Spectrin is the major constituent of the cytoskeletal network underlying the erythrocyte plasma membrane. It associates with band 4.1 and actin to form the cytoskeletal superstructure of the erythrocyte plasma membrane				0.0000	0.0000	0.0000		182860 [SPTA1 (confirmed) Elliptocytosis-2,130600|Pyropoikilocytosis,266140|Spherocytosis,type 3,270970];												0	0					SPTA1 (inh=AR+AD pLI=0.00)	0						
chr1	158589270	158589270	C	T	0.3699	73	0.0000	98	off-target	168	SPTA1	upstream_gene_variant,downstream_gene_variant,intron_variant	SPTA1:ENST00000481212:upstream_gene_variant:MODIFIER::n.-4945G>A:,SPTA1:ENST00000498708:upstream_gene_variant:MODIFIER::n.-1912G>A:,SPTA1:ENST00000492934:upstream_gene_variant:MODIFIER::n.-1379G>A:,SPTA1:ENST00000461624:downstream_gene_variant:MODIFIER::n.*3239G>A:,SPTA1:ENST00000368147:intron_variant:MODIFIER:exon44/51:c.6418-146G>A:,SPTA1:ENST00000484520:intron_variant:MODIFIER:exon1/1:n.621-146G>A:			Spectrin is the major constituent of the cytoskeletal network underlying the erythrocyte plasma membrane. It associates with band 4.1 and actin to form the cytoskeletal superstructure of the erythrocyte plasma membrane				0.0000	0.0000	0.0000		182860 [SPTA1 (confirmed) Elliptocytosis-2,130600|Pyropoikilocytosis,266140|Spherocytosis,type 3,270970];												0	0					SPTA1 (inh=AR+AD pLI=0.00)	1	I18R015_Higuita,					
chr1	158604303	158604303	G	A	0.2518	566	0.0000	386	off-target	411	SPTA1	downstream_gene_variant,intron_variant	SPTA1:ENST00000465741:downstream_gene_variant:MODIFIER::n.*4716C>T:,SPTA1:ENST00000368147:intron_variant:MODIFIER:exon39/51:c.5565+30C>T:,SPTA1:ENST00000461624:intron_variant:MODIFIER:exon1/4:n.111+30C>T:			Spectrin is the major constituent of the cytoskeletal network underlying the erythrocyte plasma membrane. It associates with band 4.1 and actin to form the cytoskeletal superstructure of the erythrocyte plasma membrane				0.0000	0.0000	0.0000		182860 [SPTA1 (confirmed) Elliptocytosis-2,130600|Pyropoikilocytosis,266140|Spherocytosis,type 3,270970];												0	0					SPTA1 (inh=AR+AD pLI=0.00)	0						
chr1	158621433	158621433	C	T	0.3333	15	0.0000	23	depth-tum;off-target	56	SPTA1	intron_variant	SPTA1:ENST00000368147:intron_variant:MODIFIER:exon23/51:c.3376-175G>A:			Spectrin is the major constituent of the cytoskeletal network underlying the erythrocyte plasma membrane. It associates with band 4.1 and actin to form the cytoskeletal superstructure of the erythrocyte plasma membrane			rs561060015	0.0000	0.0000	0.0000		182860 [SPTA1 (confirmed) Elliptocytosis-2,130600|Pyropoikilocytosis,266140|Spherocytosis,type 3,270970];												0	0					SPTA1 (inh=AR+AD pLI=0.00)	0						
chr1	158813054	158813054	C	T	0.1862	147	0.0000	114		131	MNDA	upstream_gene_variant,downstream_gene_variant,intron_variant	MNDA:ENST00000438394:upstream_gene_variant:MODIFIER::c.-2638C>T:,MNDA:ENST00000491210:downstream_gene_variant:MODIFIER::n.*541C>T:,MNDA:ENST00000368141:intron_variant:MODIFIER:exon2/6:c.266-15C>T:			May act as a transcriptional activator/repressor in the myeloid lineage. Plays a role in the granulocyte/monocyte cell- specific response to interferon. Stimulates the DNA binding of the transcriptional repressor protein YY1				0.0000	0.0000	0.00000														0	0					MNDA (inh=n/a pLI=0.00)	0		not protein-affecting	ambiguous	ENST00000368141	MNDA	IntronicSNV
chr1	170835629	170835629	C	T	0.2652	132	0.0000	103	off-target	152	PRRX1-MROH9	intergenic_region	PRRX1-MROH9:ENSG00000116132-ENSG00000117501:intergenic_region:MODIFIER::n.170835629C>T:							0.0000	0.0000	0.0000														0	0					PRRX1-MROH9 (inh=n/a pLI=n/a)	0						
chr1	182696159	182696159	C	T	0.2806	670	0.0048	416	off-target	441	RP11-317P15.3-RP11-317P15.6	intergenic_region	RP11-317P15.3-RP11-317P15.6:ENSG00000227181-ENSG00000271269:intergenic_region:MODIFIER::n.182696159C>T:						rs184203508	0.00159744	0.0000	0.0000														0	0					RP11-317P15.3-RP11-317P15.6 (inh=n/a pLI=n/a)	0						
chr1	198713088	198713088	G	A	0.3015	136	0.0000	124	off-target	152	PTPRC	intron_variant	PTPRC:ENST00000442510:intron_variant:MODIFIER:exon25/32:c.2698-95G>A:,PTPRC:ENST00000352140:intron_variant:MODIFIER:exon24/31:c.2548-95G>A:,PTPRC:ENST00000367376:intron_variant:MODIFIER:exon25/32:c.2692-95G>A:,PTPRC:ENST00000594404:intron_variant:MODIFIER:exon22/29:c.2209-95G>A:,PTPRC:ENST00000348564:intron_variant:MODIFIER:exon22/29:c.2215-95G>A:		Cell adhesion molecules (CAMs);T cell receptor signaling pathway;Primary immunodeficiency	Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity (By similarity)	Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor;B Lymphocyte Cell Surface Molecules;Lck and Fyn tyrosine kinases in initiation of TCR Activation;T Cytotoxic Cell Surface Molecules;T Helper Cell Surface Molecules		rs193178888	0.000199681	0.0000	0.0000		151460 [PTPRC (confirmed) Hepatitis C virus,susceptibility to,609532|Severe combined immunodeficiency,T cell-negative,B-cell/natural killer-cell positive,608971];												0	0					PTPRC (inh=AR pLI=1.00)	0						
chr1	201981649	201981649	C	T	0.3578	208	0.0032	312	off-target	338	RP11-465N4.4,ELF3,RP11-510N19.5	upstream_gene_variant,downstream_gene_variant,intron_variant,non_coding_transcript_exon_variant	RP11-465N4.4:ENST00000419190:upstream_gene_variant:MODIFIER::n.-2168G>A:,ELF3:ENST00000479874:upstream_gene_variant:MODIFIER::n.-48C>T:,ELF3:ENST00000475698:upstream_gene_variant:MODIFIER::n.-1257C>T:,ELF3:ENST00000498017:downstream_gene_variant:MODIFIER::n.*713C>T:,ELF3:ENST00000359651:intron_variant:MODIFIER:exon3/7:c.478+85C>T:,RP11-510N19.5:ENST00000504773:intron_variant:MODIFIER:exon1/1:n.215+937C>T:,ELF3:ENST00000367284:intron_variant:MODIFIER:exon4/8:c.478+85C>T:,ELF3:ENST00000367283:intron_variant:MODIFIER:exon4/8:c.478+85C>T:,ELF3:ENST00000490203:intron_variant:MODIFIER:exon2/4:n.588+85C>T:,ELF3:ENST00000446188:intron_variant:MODIFIER:exon4/6:c.472+85C>T:,ELF3:ENST00000495848:non_coding_transcript_exon_variant:MODIFIER:exon3/3:n.849C>T:,ELF3:ENST00000470384:non_coding_transcript_exon_variant:MODIFIER:exon1/3:n.77C>T:			Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT]. Acts synergistically with POU2F3 to transactivate the SPRR2A promoter and with RUNX1 to transactivate the ANGPT1 promoter. Also transactivates collagenase, CCL20, CLND7, FLG, KRT8, NOS2, PTGS2, SPRR2B, TGFBR2 and TGM3 promoters. Represses KRT4 promoter activity. Involved in mediating vascular inflammation. May play an important role in epithelial cell differentiation and tumorigenesis. May be a critical downstream effector of the ERBB2 signaling pathway. May be associated with mammary gland development and involution. Plays an important role in the regulation of transcription with TATA-less promoters in preimplantation embryos, which is essential in preimplantation development (By similarity)				0.0000	0.0000	0.0000														0	0					RP11-465N4.4 (inh=n/a pLI=n/a), ELF3 (inh=n/a pLI=0.98), RP11-510N19.5 (inh=n/a pLI=n/a)	0						
chr1	201982091	201982091	G	A	0.3238	282	0.0000	353		417	ELF3,RP11-465N4.4,RP11-510N19.5	synonymous_variant,upstream_gene_variant,downstream_gene_variant,intron_variant,non_coding_transcript_exon_variant	ELF3:ENST00000359651:synonymous_variant:LOW:exon5/8:c.615G>A:p.Arg205Arg,ELF3:ENST00000367284:synonymous_variant:LOW:exon6/9:c.615G>A:p.Arg205Arg,ELF3:ENST00000367283:synonymous_variant:LOW:exon6/9:c.615G>A:p.Arg205Arg,ELF3:ENST00000446188:synonymous_variant:LOW:exon6/7:c.609G>A:p.Arg203Arg,RP11-465N4.4:ENST00000419190:upstream_gene_variant:MODIFIER::n.-2610C>T:,ELF3:ENST00000475698:upstream_gene_variant:MODIFIER::n.-815G>A:,ELF3:ENST00000495848:downstream_gene_variant:MODIFIER::n.*392G>A:,ELF3:ENST00000498017:downstream_gene_variant:MODIFIER::n.*1155G>A:,RP11-510N19.5:ENST00000504773:intron_variant:MODIFIER:exon1/1:n.215+1379G>A:,ELF3:ENST00000490203:non_coding_transcript_exon_variant:MODIFIER:exon4/5:n.725G>A:,ELF3:ENST00000470384:non_coding_transcript_exon_variant:MODIFIER:exon2/3:n.332G>A:,ELF3:ENST00000479874:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.298G>A:			Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT]. Acts synergistically with POU2F3 to transactivate the SPRR2A promoter and with RUNX1 to transactivate the ANGPT1 promoter. Also transactivates collagenase, CCL20, CLND7, FLG, KRT8, NOS2, PTGS2, SPRR2B, TGFBR2 and TGM3 promoters. Represses KRT4 promoter activity. Involved in mediating vascular inflammation. May play an important role in epithelial cell differentiation and tumorigenesis. May be a critical downstream effector of the ERBB2 signaling pathway. May be associated with mammary gland development and involution. Plays an important role in the regulation of transcription with TATA-less promoters in preimplantation embryos, which is essential in preimplantation development (By similarity)				0.0000	0.0000	0.0000														0	0					ELF3 (inh=n/a pLI=0.98), RP11-465N4.4 (inh=n/a pLI=n/a), RP11-510N19.5 (inh=n/a pLI=n/a)	0		not protein-affecting	LoF	ENST00000359651	ELF3	Synonymous
chr1	206648451	206648451	T	C	0.2542	59	0.0000	97	off-target	126	IKBKE	upstream_gene_variant,intron_variant,non_coding_transcript_exon_variant	IKBKE:ENST00000492570:upstream_gene_variant:MODIFIER::n.-4958T>C:,IKBKE:ENST00000367120:intron_variant:MODIFIER:exon5/21:c.358+114T>C:,IKBKE:ENST00000537984:intron_variant:MODIFIER:exon4/20:c.103+114T>C:,IKBKE:ENST00000463979:non_coding_transcript_exon_variant:MODIFIER:exon4/4:n.676T>C:		Toll-like receptor signaling pathway	Phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. May play a special role in the immune response. Protects cells against DNA damage- induced cell death				0.0000	0.0000	0.0000														0	0					IKBKE (inh=n/a pLI=0.62)	0						
chr1	206658326	206658326	C	T	0.2772	538	0.0000	373		436	IKBKE	splice_region_variant&intron_variant,downstream_gene_variant	IKBKE:ENST00000367120:splice_region_variant&intron_variant:LOW:exon13/21:c.1428-8C>T:,IKBKE:ENST00000537984:splice_region_variant&intron_variant:LOW:exon12/20:c.1173-8C>T:,IKBKE:ENST00000492570:downstream_gene_variant:MODIFIER::n.*1585C>T:		Toll-like receptor signaling pathway	Phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. May play a special role in the immune response. Protects cells against DNA damage- induced cell death				0.0000	0.0000	0.0000														0	0					IKBKE (inh=n/a pLI=0.62)	0		not protein-affecting		ENST00000367120	IKBKE	IntronicSNV
chr2	29551063	29551063	C	T	0.3043	23	0.0000	31	off-target	81	ALK	intron_variant	ALK:ENST00000389048:intron_variant:MODIFIER:exon6/28:c.1414+153G>A:,ALK:ENST00000431873:intron_variant:MODIFIER:exon2/3:c.792-120152G>A:			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK				0.0000	0.0000	0.0000		105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];												0	0					ALK (inh=n/a pLI=0.53)	0						
chr2	29917789	29917789	G	A	0.4068	560	0.0000	352		631	ALK	synonymous_variant,intron_variant	ALK:ENST00000389048:synonymous_variant:LOW:exon3/29:c.879C>T:p.Ile293Ile,ALK:ENST00000431873:intron_variant:MODIFIER:exon2/3:c.791+22651C>T:			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK				0.0000	0.0000	0.0000	COSM3581010	105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];												0	0					ALK (inh=n/a pLI=0.53)	0		not protein-affecting	Act	ENST00000389048	ALK	Synonymous
chr2	52799754	52799754	G	A	0.2857	21	0.0000	15	depth-nor;off-target	37	AC139712.2,AC139712.2-FTH1P6	downstream_gene_variant,intergenic_region	AC139712.2:ENST00000378256:downstream_gene_variant:MODIFIER::n.*94G>A:,AC139712.2-FTH1P6:ENSG00000204993-ENSG00000233083:intergenic_region:MODIFIER::n.52799754G>A:							0.0000	0.0000	0.0000														0	0					AC139712.2 (inh=n/a pLI=n/a), AC139712.2-FTH1P6 (inh=n/a pLI=n/a)	0						
chr2	61121500	61121500	G	A	0.3169	184	0.0000	100	off-target	164	REL	intron_variant	REL:ENST00000295025:intron_variant:MODIFIER:exon2/10:c.154-32G>A:,REL:ENST00000394479:intron_variant:MODIFIER:exon2/9:c.154-32G>A:			Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF- kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator				0.0000	0.0000	0.0000														0	0					REL (inh=n/a pLI=0.95)	0						
chr2	66352893	66352893	G	A	0.2967	91	0.0000	75	off-target	125	AC074391.1-AC118345.1	intergenic_region	AC074391.1-AC118345.1:ENSG00000204929-ENSG00000227293:intergenic_region:MODIFIER::n.66352893G>A:						rs535337081	0.000199681	0.0000	0.0000														0	0					AC074391.1-AC118345.1 (inh=n/a pLI=n/a)	2	SomaticAndTreatment,					
chr2	108487513	108487513	C	T	0.2654	211	0.0000	172	off-target	215	RGPD4	missense_variant	RGPD4:ENST00000354986:missense_variant:MODERATE:exon20/23:c.3053C>T:p.Ser1018Phe,RGPD4:ENST00000408999:missense_variant:MODERATE:exon20/23:c.3053C>T:p.Ser1018Phe							0.0000	0.0000	0.0000					1.921000	T	D,D,D	B	T,T	22.00				0	0					RGPD4 (inh=n/a pLI=n/a)	0						
chr2	113147931	113147933	ATG	-	0.7500	12	0.0000	8	depth-tum;depth-nor;off-target	1	RGPD8	downstream_gene_variant,intron_variant	RGPD8:ENST00000330575:downstream_gene_variant:MODIFIER::c.*2751_*2753delCAT:,RGPD8:ENST00000302558:intron_variant:MODIFIER:exon19/22:c.2698-109_2698-107delCAT:,RGPD8:ENST00000409750:intron_variant:MODIFIER:exon18/21:c.2278-109_2278-107delCAT:,RGPD8:ENST00000522286:intron_variant:MODIFIER:exon15/15:c.*1785-109_*1785-107delCAT:						rs372712627	0.0000	0.0000	0.0000														0	0					RGPD8 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,					
chr2	113987838	113987838	C	G	0.2143	476	0.0000	377		334	PAX8,PAX8-AS1	intron_variant	PAX8:ENST00000429538:intron_variant:MODIFIER:exon9/11:c.1088-3005G>C:,PAX8-AS1:ENST00000456685:intron_variant:MODIFIER:exon3/5:n.382-255C>G:,PAX8:ENST00000263335:intron_variant:MODIFIER:exon7/9:c.778-3005G>C:,PAX8:ENST00000348715:intron_variant:MODIFIER:exon9/11:c.1009-3005G>C:,PAX8:ENST00000397647:intron_variant:MODIFIER:exon7/8:c.778-10083G>C:,PAX8:ENST00000465084:intron_variant:MODIFIER:exon1/3:c.50-3005G>C:,PAX8:ENST00000497038:intron_variant:MODIFIER:exon3/5:c.*533-3005G>C:,PAX8:ENST00000468980:intron_variant:MODIFIER:exon2/4:c.254-3005G>C:,PAX8:ENST00000263334:intron_variant:MODIFIER:exon8/9:c.1009-3005G>C:,PAX8:ENST00000485840:intron_variant:MODIFIER:exon2/2:n.1098-3005G>C:		Thyroid cancer	Transcription factor for the thyroid-specific expression of the genes exclusively expressed in the thyroid cell type, maintaining the functional differentiation of such cells				0.0000	0.0000	0.0000		167415 [PAX8 (confirmed) Hypothyroidism,congenital,due to thyroid dysgenesis or hypoplasia,218700];												0	0					PAX8 (inh=AD pLI=0.86), PAX8-AS1 (inh=n/a pLI=n/a)	0		not protein-affecting	Act	ENST00000429538	PAX8	IntronicSNV
chr2	113995195	113995195	C	T	0.4468	1311	0.0000	767		1510	RP11-65I12.1,PAX8,PAX8-AS1	upstream_gene_variant,downstream_gene_variant,intron_variant,non_coding_transcript_exon_variant	RP11-65I12.1:ENST00000553319:upstream_gene_variant:MODIFIER::n.-3112C>T:,PAX8:ENST00000465084:upstream_gene_variant:MODIFIER::c.-2176G>A:,PAX8:ENST00000485840:upstream_gene_variant:MODIFIER::n.-110G>A:,PAX8:ENST00000554352:upstream_gene_variant:MODIFIER::n.-689G>A:,PAX8-AS1:ENST00000431844:downstream_gene_variant:MODIFIER::n.*1261C>T:,PAX8:ENST00000467778:downstream_gene_variant:MODIFIER::n.*3460G>A:,PAX8:ENST00000554830:downstream_gene_variant:MODIFIER::c.*5090G>A:,PAX8:ENST00000429538:intron_variant:MODIFIER:exon7/11:c.778-897G>A:,PAX8-AS1:ENST00000422956:intron_variant:MODIFIER:exon1/4:n.35+2048C>T:,PAX8-AS1:ENST00000456685:intron_variant:MODIFIER:exon4/5:n.483-472C>T:,PAX8:ENST00000263335:intron_variant:MODIFIER:exon7/9:c.777+3933G>A:,PAX8:ENST00000348715:intron_variant:MODIFIER:exon7/11:c.778-897G>A:,PAX8:ENST00000397647:intron_variant:MODIFIER:exon7/8:c.777+3933G>A:,PAX8:ENST00000497038:intron_variant:MODIFIER:exon1/5:c.*223-897G>A:,PAX8:ENST00000468980:intron_variant:MODIFIER:exon1/4:c.133-897G>A:,PAX8:ENST00000263334:intron_variant:MODIFIER:exon6/9:c.778-897G>A:,PAX8-AS1:ENST00000437551:intron_variant:MODIFIER:exon1/2:n.45-472C>T:,PAX8-AS1:ENST00000451179:intron_variant:MODIFIER:exon1/4:n.42-472C>T:,PAX8-AS1:ENST00000556070:intron_variant:MODIFIER:exon1/2:n.35+2048C>T:,PAX8-AS1:ENST00000553869:intron_variant:MODIFIER:exon1/3:n.32-472C>T:,PAX8-AS1:ENST00000333145:intron_variant:MODIFIER:exon2/5:n.132+1005C>T:,PAX8-AS1:ENST00000445745:intron_variant:MODIFIER:exon1/4:n.377+1005C>T:,PAX8-AS1:ENST00000436293:intron_variant:MODIFIER:exon1/5:n.354+996C>T:,PAX8-AS1:ENST00000555766:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.85C>T:		Thyroid cancer	Transcription factor for the thyroid-specific expression of the genes exclusively expressed in the thyroid cell type, maintaining the functional differentiation of such cells				0.0000	0.0000	0.0000		167415 [PAX8 (confirmed) Hypothyroidism,congenital,due to thyroid dysgenesis or hypoplasia,218700];												0	0					RP11-65I12.1 (inh=n/a pLI=n/a), PAX8 (inh=AD pLI=0.86), PAX8-AS1 (inh=n/a pLI=n/a)	0		not protein-affecting	Act	ENST00000429538	PAX8	IntronicSNV
chr2	132021914	132021914	C	T	0.1667	78	0.0000	47	off-target	83	POTEE,PLEKHB2,AC131180.1	synonymous_variant,3_prime_UTR_variant,intron_variant,non_coding_transcript_exon_variant	POTEE:ENST00000356920:synonymous_variant:LOW:exon15/15:c.2886C>T:p.Phe962Phe,POTEE:ENST00000358087:3_prime_UTR_variant:MODIFIER:exon14/14:c.*1660C>T:,PLEKHB2:ENST00000303908:intron_variant:MODIFIER:exon5/5:c.424-88679C>T:,PLEKHB2:ENST00000404460:intron_variant:MODIFIER:exon6/6:c.424-88679C>T:,AC131180.1:ENST00000514256:non_coding_transcript_exon_variant:MODIFIER:exon15/15:n.2575C>T:			Involved in retrograde transport of recycling endosomes				0.0000	0.0000	0.0000														0	0					POTEE (inh=n/a pLI=n/a), PLEKHB2 (inh=n/a pLI=0.00), AC131180.1 (inh=n/a pLI=n/a)	0						
chr2	139311909	139311909	C	T	0.3211	329	0.0000	208	off-target	310	SPOPL	downstream_gene_variant,intron_variant	SPOPL:ENST00000430968:downstream_gene_variant:MODIFIER::c.*3347C>T:,SPOPL:ENST00000280098:intron_variant:MODIFIER:exon5/10:c.480+1658C>T:,SPOPL:ENST00000420679:intron_variant:MODIFIER:exon4/10:c.481-100C>T:			Component of a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, but with relatively low efficiency. Cullin-RING-based BCR (BTB-CUL3- RBX1) E3 ubiquitin-protein ligase complexes containing homodimeric SPOPL or the heterodimer formed by SPOP and SPOPL are less efficient than ubiquitin ligase complexes containing only SPOP. May function to down-regulate the activity of cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes that contain SPOP				0.0000	0.0000	0.0000														0	0					SPOPL (inh=n/a pLI=0.03)	0						
chr2	141526870	141526870	C	T	0.2382	677	0.0000	499		462	LRP1B	synonymous_variant	LRP1B:ENST00000389484:synonymous_variant:LOW:exon35/91:c.5670G>A:p.Arg1890Arg			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis			rs202221349	0.000199681	0.0000	0.0000														0	0					LRP1B (inh=n/a pLI=1.00)	0		not protein-affecting	LoF	ENST00000389484	LRP1B	Synonymous
chr2	141526959	141526959	G	A	0.2507	376	0.0000	362	off-target	321	LRP1B	intron_variant	LRP1B:ENST00000389484:intron_variant:MODIFIER:exon34/90:c.5627-46C>T:			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis				0.0000	0.0000	0.0000														0	0					LRP1B (inh=n/a pLI=1.00)	0						
chr2	141708010	141708010	C	T	0.2337	415	0.0000	314	off-target	307	LRP1B	intron_variant	LRP1B:ENST00000389484:intron_variant:MODIFIER:exon19/90:c.2969-39G>A:,LRP1B:ENST00000434794:intron_variant:MODIFIER:exon4/13:c.404-39G>A:			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis				0.0000	0.0000	0.0000														0	0					LRP1B (inh=n/a pLI=1.00)	0						
chr2	141819455	141819455	C	T	0.4286	14	0.0000	44	depth-tum;off-target	98	LRP1B	intron_variant	LRP1B:ENST00000389484:intron_variant:MODIFIER:exon8/90:c.1236+165G>A:,LRP1B:ENST00000434794:intron_variant:MODIFIER:exon2/13:c.206-79610G>A:			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis				0.0000	0.0000	0.0000														0	0					LRP1B (inh=n/a pLI=1.00)	0						
chr2	178097790	178097790	C	A	0.3077	13	0.0000	11	depth-tum;depth-nor;off-target	18	NFE2L2,DNAJC19P5	3_prime_UTR_variant,upstream_gene_variant,downstream_gene_variant,intron_variant	NFE2L2:ENST00000423513:3_prime_UTR_variant:MODIFIER:exon3/3:c.*116G>T:,DNAJC19P5:ENST00000443295:upstream_gene_variant:MODIFIER::n.-3556G>T:,NFE2L2:ENST00000458603:upstream_gene_variant:MODIFIER::c.-575G>T:,NFE2L2:ENST00000477534:downstream_gene_variant:MODIFIER::n.*415G>T:,NFE2L2:ENST00000462023:downstream_gene_variant:MODIFIER::n.*817G>T:,NFE2L2:ENST00000397062:intron_variant:MODIFIER:exon3/4:c.402+188G>T:,NFE2L2:ENST00000397063:intron_variant:MODIFIER:exon3/4:c.354+188G>T:,NFE2L2:ENST00000446151:intron_variant:MODIFIER:exon3/4:c.354+188G>T:,NFE2L2:ENST00000464747:intron_variant:MODIFIER:exon6/7:c.354+188G>T:,NFE2L2:ENST00000449627:intron_variant:MODIFIER:exon2/2:c.193+1014G>T:,NFE2L2:ENST00000448782:intron_variant:MODIFIER:exon3/4:c.354+188G>T:,NFE2L2:ENST00000430047:intron_variant:MODIFIER:exon2/2:c.64-1132G>T:,NFE2L2:ENST00000586532:intron_variant:MODIFIER:exon4/5:c.399+188G>T:,NFE2L2:ENST00000421929:intron_variant:MODIFIER:exon3/4:c.354+188G>T:,NFE2L2:ENST00000588123:intron_variant:MODIFIER:exon4/4:c.354+188G>T:		Prion disease	Transcription activator that binds to antioxidant response (ARE) elements in the promoter regions of target genes. Important for the coordinated up-regulation of genes in response to oxidative stress. May be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region				0.0000	0.0000	0.0000		600492 [NFE2L2 (provisional) Immunodeficiency,developmental delay,and hypohomocysteinemia,617744];												0	0					NFE2L2 (inh=n/a pLI=0.61), DNAJC19P5 (inh=n/a pLI=n/a)	4	SomaticAndTreatment,TEST_SomaticAndTreatment,					
chr2	189855725	189855725	C	T	0.1878	245	0.0000	186		179	COL3A1	splice_region_variant&intron_variant,upstream_gene_variant	COL3A1:ENST00000304636:splice_region_variant&intron_variant:LOW:exon10/50:c.799-5C>T:,COL3A1:ENST00000317840:splice_region_variant&intron_variant:LOW:exon10/41:c.799-5C>T:,COL3A1:ENST00000450867:upstream_gene_variant:MODIFIER::c.-676C>T:		Cell Communication;Focal adhesion;ECM-receptor interaction	Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. Is the major ligand of GPR56 in the developing brain and binding to GPR56 inhibits neuronal migration and activates the RhoA pathway by coupling GPR56 to GNA13 and possibly GNA12				0.0000	0.0000	0.0000		120180 [COL3A1 (confirmed) Ehlers-Danlos syndrome,vascular type,130050];												0	0					COL3A1 (inh=AD pLI=1.00)	0		not protein-affecting		ENST00000304636	COL3A1	IntronicSNV
chr2	189869125	189869125	C	T	0.2936	545	0.0000	360	off-target	448	COL3A1	upstream_gene_variant,downstream_gene_variant,intron_variant	COL3A1:ENST00000487010:upstream_gene_variant:MODIFIER::n.-3903C>T:,COL3A1:ENST00000467886:downstream_gene_variant:MODIFIER::n.*482C>T:,COL3A1:ENST00000304636:intron_variant:MODIFIER:exon40/50:c.2931+35C>T:,COL3A1:ENST00000317840:intron_variant:MODIFIER:exon36/41:c.2521-1226C>T:		Cell Communication;Focal adhesion;ECM-receptor interaction	Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. Is the major ligand of GPR56 in the developing brain and binding to GPR56 inhibits neuronal migration and activates the RhoA pathway by coupling GPR56 to GNA13 and possibly GNA12				0.0000	0.0000	0.0000		120180 [COL3A1 (confirmed) Ehlers-Danlos syndrome,vascular type,130050];												0	0					COL3A1 (inh=AD pLI=1.00)	0						
chr2	189870140	189870140	G	A	0.3569	954	0.0000	482		769	COL3A1	missense_variant,upstream_gene_variant,downstream_gene_variant,intron_variant	COL3A1:ENST00000304636:missense_variant:MODERATE:exon41/51:c.2996G>A:p.Gly999Asp,COL3A1:ENST00000487010:upstream_gene_variant:MODIFIER::n.-2888G>A:,COL3A1:ENST00000467886:downstream_gene_variant:MODIFIER::n.*1497G>A:,COL3A1:ENST00000317840:intron_variant:MODIFIER:exon36/41:c.2521-211G>A:		Cell Communication;Focal adhesion;ECM-receptor interaction	Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. Is the major ligand of GPR56 in the developing brain and binding to GPR56 inhibits neuronal migration and activates the RhoA pathway by coupling GPR56 to GNA13 and possibly GNA12				0.0000	0.0000	0.0000		120180 [COL3A1 (confirmed) Ehlers-Danlos syndrome,vascular type,130050];		CM1314431 [CLASS=DM? MUT=ALT PHEN="Ehlers-Danlos syndrome" GENE=COL3A1]; 	9.869000	D	D	D	D	33.00				0	0					COL3A1 (inh=AD pLI=1.00)	0		predicted passenger		ENST00000304636	COL3A1	Missense
chr2	189870933	189870933	G	A	0.2866	802	0.0000	476		540	COL3A1	missense_variant&splice_region_variant,upstream_gene_variant,downstream_gene_variant,intron_variant	COL3A1:ENST00000304636:missense_variant&splice_region_variant:MODERATE:exon42/51:c.3041G>A:p.Gly1014Glu,COL3A1:ENST00000487010:upstream_gene_variant:MODIFIER::n.-2095G>A:,COL3A1:ENST00000467886:downstream_gene_variant:MODIFIER::n.*2290G>A:,COL3A1:ENST00000317840:intron_variant:MODIFIER:exon37/41:c.2525+578G>A:		Cell Communication;Focal adhesion;ECM-receptor interaction	Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. Is the major ligand of GPR56 in the developing brain and binding to GPR56 inhibits neuronal migration and activates the RhoA pathway by coupling GPR56 to GNA13 and possibly GNA12			rs121912916	0.0000	0.0000	0.0000	COSM2711938	120180 [COL3A1 (confirmed) Ehlers-Danlos syndrome,vascular type,130050];	17215 [pathogenic DISEASE=ehlers-danlos_syndrome,_type_4]; 	CM920209 [CLASS=DM MUT=ALT PHEN="Ehlers-Danlos syndrome IV" GENE=COL3A1]; 	9.827000	D	D	D	D	33.00				0	0					COL3A1 (inh=AD pLI=1.00)	1	I18R015_Higuita,	predicted passenger		ENST00000304636	COL3A1	Missense
chr2	198299845	198299845	C	T	0.3188	161	0.0000	119	off-target	195	SF3B1,SF3B1-RNU6-1029P	upstream_gene_variant,intergenic_region	SF3B1:ENST00000335508:upstream_gene_variant:MODIFIER::c.-122G>A:,SF3B1:ENST00000409915:upstream_gene_variant:MODIFIER::c.-122G>A:,SF3B1:ENST00000414963:upstream_gene_variant:MODIFIER::c.-122G>A:,SF3B1:ENST00000487698:upstream_gene_variant:MODIFIER::c.-122G>A:,SF3B1:ENST00000414174:upstream_gene_variant:MODIFIER::c.-122G>A:,SF3B1-RNU6-1029P:ENSG00000115524-ENSG00000206836:intergenic_region:MODIFIER::n.198299845C>T:			Subunit of the splicing factor SF3B required for 'A' complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence (BPS) in pre-mRNA. Sequence independent binding of SF3A/SF3B complex upstream of the branch site is essential, it may anchor U2 snRNP to the pre-mRNA. May also be involved in the assembly of the 'E' complex. Belongs also to the minor U12-dependent spliceosome, which is involved in the splicing of rare class of nuclear pre-mRNA intron				0.0000	0.0000	0.0000														0	0					SF3B1 (inh=n/a pLI=1.00), SF3B1-RNU6-1029P (inh=n/a pLI=n/a)	0						
chr2	202134382	202134382	G	A	0.2343	672	0.0000	424	off-target	420	CASP8	upstream_gene_variant,intron_variant	CASP8:ENST00000424461:upstream_gene_variant:MODIFIER::c.-2979G>A:,CASP8:ENST00000444430:upstream_gene_variant:MODIFIER::c.-2979G>A:,CASP8:ENST00000358485:intron_variant:MODIFIER:exon2/8:c.483-1857G>A:,CASP8:ENST00000392263:intron_variant:MODIFIER:exon3/8:c.306-1857G>A:,CASP8:ENST00000264274:intron_variant:MODIFIER:exon3/6:c.306-1857G>A:,CASP8:ENST00000392259:intron_variant:MODIFIER:exon3/8:c.306-1857G>A:,CASP8:ENST00000392266:intron_variant:MODIFIER:exon3/7:c.306-1857G>A:,CASP8:ENST00000432109:intron_variant:MODIFIER:exon3/9:c.306-1857G>A:,CASP8:ENST00000264275:intron_variant:MODIFIER:exon4/9:c.401+54G>A:,CASP8:ENST00000471383:intron_variant:MODIFIER:exon3/4:n.582-1857G>A:,CASP8:ENST00000450491:intron_variant:MODIFIER:exon2/5:c.-4-1857G>A:,CASP8:ENST00000440732:intron_variant:MODIFIER:exon3/3:c.306-1857G>A:,CASP8:ENST00000392258:intron_variant:MODIFIER:exon3/7:c.306-1857G>A:,CASP8:ENST00000447616:intron_variant:MODIFIER:exon2/4:c.306-1857G>A:,CASP8:ENST00000437283:intron_variant:MODIFIER:exon2/3:c.*280-1857G>A:,CASP8:ENST00000413726:intron_variant:MODIFIER:exon2/4:c.306-1857G>A:,CASP8:ENST00000490412:intron_variant:MODIFIER:exon1/2:n.37-1857G>A:,CASP8:ENST00000339403:intron_variant:MODIFIER:exon2/8:n.391-1857G>A:,CASP8:ENST00000323492:intron_variant:MODIFIER:exon2/7:c.306-1857G>A:,CASP8:ENST00000429881:intron_variant:MODIFIER:exon2/2:c.306-1857G>A:		Neurodegenerative Diseases;p53 signaling pathway;Apoptosis;Toll-like receptor signaling pathway;Huntington's disease;Dentatorubropallidoluysian atrophy (DRPLA)	Most upstream protease of the activation cascade of caspases responsible for the TNFRSF6/FAS mediated and TNFRSF1A induced cell death. Binding to the adapter molecule FADD recruits it to either receptor. The resulting aggregate called death- inducing signaling complex (DISC) performs CASP8 proteolytic activation. The active dimeric enzyme is then liberated from the DISC and free to activate downstream apoptotic proteases. Proteolytic fragments of the N-terminal propeptide (termed CAP3, CAP5 and CAP6) are likely retained in the DISC. Cleaves and activates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. May participate in the GZMB apoptotic pathways. Cleaves ADPRT. Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC. Likely target for the cowpox virus CRMA death inhibitory protein. Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalytic site and may interfere with the pro-apoptotic activity of the complex	Caspase Cascade in Apoptosis;Ceramide Signaling Pathway;D4-GDI Signaling Pathway;FAS signaling pathway ( CD95 );HIV-I Nef: negative effector of Fas and TNF;Induction of apoptosis through DR3 and DR4/5 Death Receptors ;Role of Mitochondria in Apoptotic Signaling;SODD/TNFR1 Signaling Pathway;TNFR1 Signaling Pathway			0.0000	0.0000	0.0000		601763 [CASP8 (confirmed) Autoimmune lymphoproliferative syndrome,type IIB,607271|Hepatocellular carcinoma,somatic,114550|Breast cancer,protection against,114480|Lung cancer,protection against,211980];												0	0					CASP8 (inh=AR+AD pLI=0.02)	0						
chr2	215145860	215145860	A	C	0.2821	281	0.0000	131	off-target	204	SPAG16,AC107218.3,RPL5P8	intron_variant,non_coding_transcript_exon_variant	SPAG16:ENST00000331683:intron_variant:MODIFIER:exon15/15:c.1721-129004A>C:,SPAG16:ENST00000406979:intron_variant:MODIFIER:exon17/17:c.*1722-129004A>C:,SPAG16:ENST00000374309:intron_variant:MODIFIER:exon13/13:c.1439-129004A>C:,SPAG16:ENST00000451561:intron_variant:MODIFIER:exon5/5:c.593-129004A>C:,SPAG16:ENST00000480494:intron_variant:MODIFIER:exon4/4:n.463-129004A>C:,AC107218.3:ENST00000412896:intron_variant:MODIFIER:exon3/3:n.304-30958T>G:,RPL5P8:ENST00000396820:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.317T>G:			Necessary for sperm flagellar function. Plays a role in motile ciliogenesis. May help to recruit STK36 to the cilium or apical surface of the cell to initiate subsequent steps of construction of the central pair apparatus of motile cilia (By similarity)				0.0000	0.0000	0.0000														0	0					SPAG16 (inh=n/a pLI=0.00), AC107218.3 (inh=n/a pLI=n/a), RPL5P8 (inh=n/a pLI=n/a)	0						
chr2	223360895	223360895	C	T	0.5000	4	0.0000	19	lt-3-reads;depth-tum;depth-nor;off-target	25	RNU6-619P,SGPP2	upstream_gene_variant,intron_variant	RNU6-619P:ENST00000365146:upstream_gene_variant:MODIFIER::n.-2115C>T:,SGPP2:ENST00000321276:intron_variant:MODIFIER:exon2/4:c.378+21450C>T:		Sphingolipid metabolism	Has specific phosphohydrolase activity towards sphingoid base 1-phosphates. Has high phosphohydrolase activity against dihydrosphingosine-1-phosphate and sphingosine-1-phosphate (S1P) in vitro. May play a role in attenuating intracellular sphingosine 1-phosphate (S1P) signaling. May play a role in pro-inflammatory signaling				0.0000	0.0000	0.0000														0	0					RNU6-619P (inh=n/a pLI=n/a), SGPP2 (inh=n/a pLI=0.05)	0						
chr2	234544964	234544964	C	T	0.4286	7	0.0000	12	depth-tum;depth-nor;off-target	22	UGT1A10,UGT1A8	upstream_gene_variant,intron_variant	UGT1A10:ENST00000344644:upstream_gene_variant:MODIFIER::c.-205C>T:,UGT1A10:ENST00000373445:upstream_gene_variant:MODIFIER::c.-205C>T:,UGT1A8:ENST00000373450:intron_variant:MODIFIER:exon1/4:c.855+17756C>T:		Pentose and glucuronate interconversions;Androgen and estrogen metabolism;Starch and sucrose metabolism;Retinol metabolism;Porphyrin and chlorophyll metabolism;Metabolism of xenobiotics by cytochrome P450;Drug metabolism - cytochrome P450;Drug metabolism - other enzymes	UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds				0.0000	0.0000	0.0000														0	0					UGT1A10 (inh=n/a pLI=0.00), UGT1A8 (inh=n/a pLI=0.00)	0						
chr2	234581345	234581345	G	A	0.3050	1497	0.0000	1026		1181	UGT1A9,UGT1A8,UGT1A10	synonymous_variant,intron_variant	UGT1A9:ENST00000354728:synonymous_variant:LOW:exon1/5:c.765G>A:p.Thr255Thr,UGT1A8:ENST00000609637:synonymous_variant:LOW:exon1/5:c.765G>A:p.Thr255Thr,UGT1A10:ENST00000344644:intron_variant:MODIFIER:exon1/4:c.855+35322G>A:,UGT1A8:ENST00000373450:intron_variant:MODIFIER:exon1/4:c.855+54137G>A:,UGT1A10:ENST00000373445:intron_variant:MODIFIER:exon1/4:c.855+35322G>A:		Pentose and glucuronate interconversions;Androgen and estrogen metabolism;Starch and sucrose metabolism;Retinol metabolism;Porphyrin and chlorophyll metabolism;Metabolism of xenobiotics by cytochrome P450;Drug metabolism - cytochrome P450;Drug metabolism - other enzymes	UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols.,UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds				0.0000	0.0000	0.00002	COSM81882													0	1					UGT1A9 (inh=n/a pLI=0.00), UGT1A8 (inh=n/a pLI=0.00), UGT1A10 (inh=n/a pLI=0.00)	0						
